Skip to content

Welcome to Discover Pharma! Today is : November 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Advanced Therapies,Central Nervous System,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Laverock Therapeutics expands into in vivo CAR-T and genetic medicine

    Laverock Therapeutics is expanding its therapeutic pipeline into in vivo [...]

    September 30, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Trixeo approved in EU for asthma

    AstraZeneca’s Trixeo has been approved in the EU as a [...]

    September 30, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Research & Development

    Merck highlights RDKit’s role in AI-driven drug discovery

    Merck has highlighted the growing role of open-source chemistry software [...]

    September 21, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Novadip secures €10.4M to advance pivotal Phase 3 trial

    Novadip Biosciences has secured €10.4 million in convertible financing to [...]

    September 21, 2026
  • Biotech & Pharma Business,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Telix to acquire ITM in $1.65BN radiopharmaceutical deal

    Telix has agreed to acquire ITM Isotope Technologies Munich in [...]

    September 21, 2026
  • Advanced Therapies,Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome

    Andelyn Biosciences is manufacturing Ultragenyx’s newly FDA-approved Fayuvi gene therapy [...]

    September 21, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Ariadne Bio launches with Parkinson’s apathy drug candidate

    Ariadne Bio has launched with funding from The Michael J [...]

    September 18, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    MaaT Pharma to advance Phase 3 trial after EMA rejects MaaT013 application

    MaaT Pharma plans to advance a global Phase 3 trial [...]

    September 18, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Genomics and sequencing,Manufacturing & Supply Chain,Research & Development

    Saudi Arabia announces biotech deals and research partnerships worth SAR 5.5BN

    Saudi Arabia has announced more than SAR 5 billion in [...]

    September 18, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Big Picture Bio launches with £2.2M to design cancer drug combinations

    Big Picture Bio has launched with £2.2 million in funding [...]

    September 18, 2026
Previous345Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SalubrisBio reports JK06 results across three cancer types
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tango reports 82% response rate in pancreatic cancer trial
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA seeks input on new rare disease drug development framework
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top